Leaked news from the future.
Tap to receive
Moderna and Merck will secure FDA approval for intismeran autogene by December 31, 2027. The decision will rest on data from the fully enrolled Phase 3 INTERPATH-001 trial, which has an interim analysis expected in the second half of 2026, and on manufacturing readiness at the dedicated Massachuset…